
Pushkala Aripaka
Deputy Editor, North America Headlines News at Reuters
She/They. N.America Biz News @Reuters. UK Biz/Health before. Alum @AmityUni @SRM_Univ. Dog Mom, Fauji kid, Feminist, Mental health. Views MINE [email protected]
Articles
-
1 week ago |
msn.com | Raechel Thankam Job |Pushkala Aripaka
Microsoft Cares About Your PrivacyMicrosoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will personalise the content and ads that you see. You can select ‘I Accept’ to consent to these uses or click on ‘Manage preferences’ to review your options and exercise your right to object to Legitimate Interest where used.
-
1 week ago |
marketscreener.com | Raechel Thankam Job |Pushkala Aripaka
(Reuters) -Recruiter Hays warned on Thursday that a reduction in new job openings recently and ongoing delays in hiring decisions would lead to a bigger-than-expected drop in profit for the year, knocking down its shares and those of European rivals. Hays said its profit for the year through June would fall more than 57% to around 45 million pounds ($60.3 million), hurt by broad weakness in permanent hiring as confidence among employers and job seekers was low due to economic uncertainty.
-
2 weeks ago |
cp24.com | Pushkala Aripaka |Tasim Zahid
AstraZeneca has signed a research agreement worth more than US$5 billion with Chinese drugmaker CSPC Pharmaceutical Group, the Anglo-Swedish drugmaker said on Friday. The deal marks the latest effort by AstraZeneca to revive its business in China, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports.
-
2 weeks ago |
today.westlaw.com | Tomasz Janowski |Pushkala Aripaka |Tasim Zahid
(Reuters) -AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic conditions, it said on Friday.
-
1 month ago |
rnz.co.nz | Davide Barbuscia |Pushkala Aripaka
By Davide Barbuscia and Pushkala Aripaka, ReutersMoody's US credit rating now at 'Aa1'Agency's outlook on the country 'stable'Moody's cites rising debt and interest costsMoody's cut the US credit rating by one notch, citing rising debt and interest payments that outpace those of similarly rated sovereigns, in a move that marks the end of an era as Moody's was the last major agency to maintain a triple-A rating for US sovereign debt.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →Coverage map
X (formerly Twitter)
- Followers
- 547
- Tweets
- 3K
- DMs Open
- Yes

RT @neuralink: We are excited to share that we have received the FDA’s approval to launch our first-in-human clinical study! This is the r…

RT @Reuters: Twitter alleges that Microsoft may have violated an agreement over using the social media company's data, according to a lette…

RT @ReutersWorld: WHO recommends new COVID shots should target only XBB variants https://t.co/s9j0a0nzlP https://t.co/AXKDT46W8m